FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2163978680> ?p ?o ?g. }

• W2163978680 endingPage "311" @default.
• W2163978680 startingPage "310" @default.
• W2163978680 abstract "Back to table of contents Previous article Next article Letter to the EditorFull AccessSympathoadrenal Hyperactivity and Neuroleptic Malignant SyndromeNASEEM AKHTAR QURESHI, M.D., , and TARIQ ALI AL-HABEEB, K.S.U.F., NASEEM AKHTAR QURESHISearch for more papers by this author, M.D., Buraidah, Saudi Arabia, and TARIQ ALI AL-HABEEBSearch for more papers by this author, K.S.U.F., Riyadh, Saudi ArabiaPublished Online:1 Feb 2000AboutSectionsView EPUB ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinked InEmail To the Editor: We read with great interest the article by Ronald J. Gurrera, M.D. (1), a distinguished researcher, regarding the etiology of neuroleptic malignant syndrome. He correctly stated that the current theories of origin—hypothalamic hypodopaminergia and direct myotoxicity—do not explain the entire pathophysiological changes found in neuroleptic malignant syndrome. He further added that the treatment options based on these mechanisms are not reliable and are reported to be insufficiently effective in overall management of the symptoms of neuroleptic malignant syndrome. Similarly, when we reviewed and updated the relevant literature (2) and presented nine cases (3) of neuroleptic malignant syndrome, one of our main conclusions was that all the manifestations of neuroleptic malignant syndrome are not explained exclusively by dopaminergic antagonism in the central nervous system. Therefore, we recommended that other putative neurotransmitters and also peripheral factors should be explored in studying its pathophysiology.The author partially bridged this gap by presenting an alternative hypothesis to that of sympathoadrenal hyperactivity, which, in a person genetically vulnerable to the development of neuroleptic malignant syndrome, is the interplay of the dysregulated and/or overactivated sympathetic nervous system in response to emotional or psychological stress. Although Dr. Gurrera did not highlight them, we feel that there are several future research implications in his article.1. Despite a recent study’s negative results (4) regarding the genetic etiology of the features of neuroleptic malignant syndrome, further studies are needed to discover the phenotypes and genetic markers of this syndrome.2. As the author claimed, this pathophysiological model explains most of the features of neuroleptic malignant syndrome; therefore, the unexplained manifestations should have been better elucidated. Their identification may in fact guide researchers to explore other possible alternative pathophysiological mechanisms underlying the development of neuroleptic malignant syndrome.3. The author did not suggest any alternative treatments based on his hypothesis; hence, the hypothesis should be the avenue in future studies for developing suitable drugs for the treatment of both neuroleptic malignant syndrome and psychological disorders.4. Finally, in the context of this new pathophysiological model, is it possible to prematurely rename neuroleptic malignant syndrome as “sympathoadrenal hyperactivity hyperpyrexia syndrome”?References1. Gurrera RJ: Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome. Am J Psychiatry 1999; 156:169–180Abstract, Google Scholar2. Qureshi NA, Al-Amri AH, Al-Beyari TH, Abdelgadir MH, Al-Habeeb TA: Neuroleptic malignant syndrome: a comprehensive review and update. Saudi Pharmaceutical J 1996; 4:138–148Google Scholar3. Qureshi NA, Al-Beyari TH, Al-Amri AH, Abdelgadir MH, Al-Habeeb TA: Neuroleptic malignant syndrome: a report of 9 suspected cases. Saudi Pharmaceutical J 1996; 4:179–189Google Scholar4. Kawanishi C, Hanihara T, Shimoda Y, Suzuki K, Sugiyama N, Onishi H, Miyakawa T, Yamada Y, Kosaka K: Lack of association between neuroleptic malignant syndrome and polymorphisms in the 5-HT1A and 5-HT2A receptor genes. Am J Psychiatry 1998; 155:1275–1277Google Scholar FiguresReferencesCited byDetailsCited byNone Volume 157Issue 2 February 2000Pages 310-a-311 Metrics History Published online 1 February 2000 Published in print 1 February 2000" @default.
• W2163978680 created "2016-06-24" @default.
• W2163978680 creator A5059146273 @default.
• W2163978680 date "2000-02-01" @default.
• W2163978680 modified "2023-10-18" @default.
• W2163978680 title "Sympathoadrenal Hyperactivity and Neuroleptic Malignant Syndrome" @default.
• W2163978680 doi "https://doi.org/10.1176/appi.ajp.157.2.310-a" @default.
• W2163978680 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10671434" @default.
• W2163978680 hasPublicationYear "2000" @default.
• W2163978680 type Work @default.
• W2163978680 sameAs 2163978680 @default.
• W2163978680 citedByCount "1" @default.
• W2163978680 countsByYear W21639786802016 @default.
• W2163978680 crossrefType "journal-article" @default.
• W2163978680 hasAuthorship W2163978680A5059146273 @default.
• W2163978680 hasConcept C10162356 @default.
• W2163978680 hasConcept C118552586 @default.
• W2163978680 hasConcept C126322002 @default.
• W2163978680 hasConcept C137627325 @default.
• W2163978680 hasConcept C15744967 @default.
• W2163978680 hasConcept C170493617 @default.
• W2163978680 hasConcept C2775864247 @default.
• W2163978680 hasConcept C2777964233 @default.
• W2163978680 hasConcept C2780179036 @default.
• W2163978680 hasConcept C37000724 @default.
• W2163978680 hasConcept C71924100 @default.
• W2163978680 hasConceptScore W2163978680C10162356 @default.
• W2163978680 hasConceptScore W2163978680C118552586 @default.
• W2163978680 hasConceptScore W2163978680C126322002 @default.
• W2163978680 hasConceptScore W2163978680C137627325 @default.
• W2163978680 hasConceptScore W2163978680C15744967 @default.
• W2163978680 hasConceptScore W2163978680C170493617 @default.
• W2163978680 hasConceptScore W2163978680C2775864247 @default.
• W2163978680 hasConceptScore W2163978680C2777964233 @default.
• W2163978680 hasConceptScore W2163978680C2780179036 @default.
• W2163978680 hasConceptScore W2163978680C37000724 @default.
• W2163978680 hasConceptScore W2163978680C71924100 @default.
• W2163978680 hasIssue "2" @default.
• W2163978680 hasLocation W21639786801 @default.
• W2163978680 hasLocation W21639786802 @default.
• W2163978680 hasOpenAccess W2163978680 @default.
• W2163978680 hasPrimaryLocation W21639786801 @default.
• W2163978680 hasRelatedWork W1491554296 @default.
• W2163978680 hasRelatedWork W2126270921 @default.
• W2163978680 hasRelatedWork W2377142024 @default.
• W2163978680 hasRelatedWork W2414548500 @default.
• W2163978680 hasRelatedWork W2498454162 @default.
• W2163978680 hasRelatedWork W2748952813 @default.
• W2163978680 hasRelatedWork W2899084033 @default.
• W2163978680 hasRelatedWork W3109432833 @default.
• W2163978680 hasRelatedWork W4213026892 @default.
• W2163978680 hasRelatedWork W84856916 @default.
• W2163978680 hasVolume "157" @default.
• W2163978680 isParatext "false" @default.
• W2163978680 isRetracted "false" @default.
• W2163978680 magId "2163978680" @default.
• W2163978680 workType "article" @default.